Epidermal growth factor receptor , and

Meisner H, Daga A, Buxton J et al 1997 Interactions of Drosophila Cbl with epidermal growth factor receptors and role of Cbl in R7 photoreceptor cell development. Mol Cell Biol 17 2217-... 

Bergmann F, Breinig M, Hopfner M, et al. Expression pattern and functional relevance of epidermal growth factor receptor and cyclooxygenase-2 novel chemotherapeutic targets in pancreatic endocrine tumors. Am. J. Gastroenterol. 2009 104 171-181. 

Kane, S. 2006. Cancer therapies targeted to the epidermal growth factor receptor and its family members. Expert Opinion on Therapeutic Patents 16(2), 147-164. 

Simeonova, P. P. et al., c-Src-dependent activation of the epidermal growth factor receptor and mitogen-activated protein kinase pathway by arsenic. Role in carcinogenesis, J. Biol. Chem., 277, 2945, 2002. 

Koyama, S., Maruyama, T., and Adachi, S. (1999). Expression of epidermal growth factor receptor and CD44 splicing variant sharing exons 6 and 9 on gastric and esophageal carcinomas a two flow-cytometric analysis. J. Cancer Res. Clin. Oncol. 125, 47—54. 

Deoxycholic acid has also been demonstrated to activate other pivotal oncogenic pathways in CRC cells in vitro including p-catenin/T-cell factor-mediated transcription, extra-cellular signal-regulated kinase activation downstream of the epidermal growth factor receptor and Jun-N-terminal kinase... 

Liu, S. M., and G. Carpenter. Differential heat stress stability of epidermal growth factor receptor and erbB-2 receptor tyrosine kinase activities. J-Cell-Physiol. 157 237-42.1993. 

Woodbum JR. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 1999 82 241-250. 

Neal DE, Mellon K. Epidermal growth factor receptor and bladder cancer a review. Urol Int 1992 48 365-371. 

In comparison to the level of cellular serine or threonine phosphorylation, protein tyrosine phosphorylation occurs at quite low levels in normal cells but dramatically increases upon oncogenic transformation or stimulation. Since the first discovery in 1978 that the transforming protein from Rous sarcoma virus (pp60vsrc) exhibited intrinsic kinase activity/5 protein kinase activity has also been shown to be inherent to other growth factor receptors such as epidermal growth factor receptor and the insulin receptor,[6 91 and to involve autophosphorylation processes. The diverse biochemical activity exhibited by protein tyrosine phosphorylation has stimulated the development of chemical methods for the preparation of phosphorylated peptides for use as substrates in elucidating the biochemical and physiological activity of phosphorylated site(s). 

Wosikowski K, Schuurhuis D, Johnson K et al. Identification of epidermal growth factor receptor and c-erbB2 pathway inhibitors by correlation with gene expression patterns. J Natl Cancer Inst 1997 89 1505-1515. 

Rusch V, Baselga J, Cordon-Cardo C et al. Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res 1993 53 2379-2385. 

Fry DW, Bridges AJ, Denny WA et al. Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor. Proc Natl Acad Sci USA 1998 95 12022-12027. 

Lager, D. J., Slagel, D. D., and Palechek, P. L. 1994. The expression of epidermal growth factor receptor and transforming growth factor a in renal cell carcinoma. Mod. Pathol. 7 544-548. 

Ngan, H. Y. S., Cheung, A. N. Y., Liu, S. S., Cheng, D. K. L., and Ng, T. Y. 2001. Abnormal expression of epidermal growth factor receptor and c-erbB2 in squamous cell carcinoma of the cervix Correlation with human papillomavirus and prognosis. Tumor Biol. 22 176-183. 

Schneider, M. R., Werner, S., Paus, 1C and Wolf, E. (2008) Beyond wavy hairs the epidermal growth factor receptor and its ligands in skin biology and pathology. Am J Pathol 173, 14-24. 

M. Schneider, F. Demard, and G. Milano. 1993. Expression of epidermal growth factor receptor and survival in upper aero-digestive tract cancer. J. Clin. Oncol. 11 1873-1878. 

KIT, Fit-3, and RET.13 It exhibited selectivity against other kinases, including MEK-1, ERK1, epidermal growth factor receptor and human insulin receptor (Table 1). 

R2. Ravenna, L., Lubrano, C., Di Silverio, F., Vacca, A., Felli, M. P., etal., Androgenic and antian-drogenic control on epidermal growth factor, epidermal growth factor receptor, and androgen receptor expression in human prostate cancer cell line LNCaP. Prostate 26, 290—298 (1995). R3. Rechler, M. M., and Nissley, S. P., Insulin-like growth factor (IGF)/somatomedin receptor subtypes structure, function and relationships to insulin receptors and IGF carrier proteins. Horm. Res. 24, 152-159 (1986). 

Scher, H. I., Sarkis, A., Reuter, V., Cohen, D., Netto, G., et al., Changing pattern of expression of the epidermal growth factor receptor and transforming growth factor alpha in the progression of prostatic neoplasms. Clin. Cancer Res. 1, 545-550 (1995). 

V8. Visakorpi, T., Kalloniemi, O. P., Koivula, T., Harvey, J., and Isola, J., Expression of epidermal growth factor receptor and erbB2 (HER-2/Neu) oncoprotein in prostatic carcinomas. Mod. Pathol. 5, 643-648 (1992). 

Downward, J., Yarden, Y, Mayes, E., Scrace, G., Totty, N., Stockwell, P., Ullrich, A., Schlessinger, J., and Waterfield, M. D. (1984). Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences. Nature 307, 521-527. 

R. B. Birge, J. E. Fajardo, B. J. Mayer, and H. Hanafusa. Tyiosine-phosphorylated epidermal growth factor receptor and cellular pi30 provide high affinity binding substrates to analyze Crk-phosphotyrosine-dependent interactions in vitro. J Biol Chem, 267 (15), 10588-10595, 1992. 

Dorai, T., Gehani, N., and Katz, A., Therapeutic potential of curcumin in human prostate cancer. II. Curcumin inhibits tyrosine kinase activity of epidermal growth factor receptor and depletes the protein, Mol. Urol., 4, 1, 2000. 

Figure 1 Signaling networks and loops. Schematic interaction maps that represent the major components in the signaling networks emanating from (a) the epidermal growth factor receptor and (b) the toll-like receptor are shown, (c) Schematics that represent several types of regulatory loops that are found in intracellular signaling networks.

Theodorescu, D., Comil, I., Sheehan, C., Man, M. S. and Kerbel, R. S. (1991a) Haras induction of the invasive phenotype results in upregulation of epidermal growth factor receptors and altered responsiveness to epidermal growth factor in human papillary transitional cell carcinoma cell. Cancer Res. 51, 4475-4491. 

Robertson, K., Reeves, J., Smith, G., Keith, W., Ozanne, B Cooke, T and Stanton, P. (1996) Quantitative estimation of epidermal growth factor receptor and c-erbB-2 in human breast cancer. Cancer Res. 56, 3823-3830. 

Richardson CM, Sharma RA, Cox G, et al. Epidermal growth factor receptors and cyclooxygenase-2 in the pathogenesis of non-small cell lung cancer potential targets for chemopreven-tion and systemic therapy. Lung Cancer. 2003 39(1) 1-13. 

Egloff AM, Grandis JR. Targeting epidermal growth factor receptor and SRC pathways in head and neck cancer. Semin Oncol. 2008 35(3) 286-297. 

B.S. Hendriks, G. Orr, A. Wells, H.S. Wiley, D.A. Lauffenburger, Parsing ERK activation reveals quantitatively equivalent contributions from epidermal growth factor receptor and HER2 in human mammary epithelial cells,/. Biol. Chem. 2005, 280, 6157-6169. 

---